Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510966 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL18160108 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL15456965 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL13708878 | 0.84 | — | — | |
| SCHEMBL5343079 | 0.84 | — | — | |
| Sorbitol SCHEMBL8039358 | 0.82 | LMNA (0.58) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL18347548 | 0.81 | AKR1B1 (0.33) | AKR1B1PAX8 | |
| SCHEMBL13384832 | 0.80 | AKR1B1 (0.42) | TDP1AKR1B1PAX8TSHR | |
| SCHEMBL260109 | 0.80 | LMNA (0.48) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL187021 | 0.80 | LMNA (0.48) | LMNAL3MBTL1TDP1AKR1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS LTD (IE) | 2018-12-06 | — | — | US | disclosed |
| EP-3229815-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | Solstice Biologics, Ltd. (IE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094677-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS, LTD. (IE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | HCCS, PNP, NT5C3B | LMNA 4101/4885L3MBTL1 2703/4885TDP1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.